PDF herunterladen
Semin Reprod Med 2006; 24(1): 040-053
DOI: 10.1055/s-2006-931800
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Obstetrical Antiphospholipid Syndrome

Serena Wu1 , Mary D. Stephenson2
  • 1Fellow, Section of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois
  • 2Professor, Section of Reproductive Endocrinology and Infertility; Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
18. Januar 2006 (online)

    Lizenzen und Reprints

ABSTRACT

Antiphospholipid syndrome (APS) is an autoimmune disease manifested by a thrombotic or obstetrical event in the presence of antiphospholipid antibodies. Obstetrical APS was initially described in the 1950s. Obstetrical features presently include recurrent pre-embryonic and embryonic miscarriage, fetal demise, preeclampsia, intrauterine growth restriction, and possibly placental abruption. Since the first description of obstetrical APS, researchers have unraveled some of the pathophysiology involved in the disease. At present, there are numerous antiphospholipid antibodies that can be measured in human serum, each of which requires evaluation with regard to whether an association with obstetrical events exists. Clinical trials have provided some insight into optimal treatment protocols, but to date, such trials are limited. On the basis of small, randomized trials, live birth rates of approximately 70 to 80% have been reported with the use of low-dose acetylsalicylic acid and heparin. Despite such encouraging results, ongoing pregnancies are fraught with maternal and fetal morbidity. This review will highlight the obstetrical morbidity associated with APS, discuss the limitations of the present criteria for diagnosis, appraise published treatment trials, and summarize directions for future study of obstetrical APS.

KEYWORDS

Antiphospholipid syndrome - antiphospholipid antibodies - recurrent miscarriage - fetal demise - heparin

REFERENCES

  • 1 Wilson W A, Gharavi A E, Koike T et al.. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.  Arthritis Rheum. 1999;  42 1309-1311
    CrossrefPubMedGoogle Scholar
  • 2 Branch D W, Silver R M, Blackwell J L, Reading J C, Scott J R. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience.  Obstet Gynecol. 1992;  80 614-620
    PubMedGoogle Scholar
  • 3 Lima F, Khamashta M A, Buchanan N M, Kerslake S, Hunt B J, Hughes G R. A study of sixty pregnancies in patients with the antiphospholipid syndrome.  Clin Exp Rheumatol. 1996;  14 131-136
    PubMedGoogle Scholar
  • 4 Backos M, Rai R, Baxter N, Chilcott I T, Cohen H, Regan L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin.  Br J Obstet Gynaecol. 1999;  106 102-107
    PubMedGoogle Scholar
  • 5 Kutteh W H, Rote N S, Silver R. Antiphospholipid antibodies and reproduction: the antiphospholipid antibody syndrome.  Am J Reprod Immunol. 1999;  41 133-152
    CrossrefPubMedGoogle Scholar
  • 6 Lockshin M D. Antiphospholipid antibody. Babies, blood clots, biology.  JAMA. 1997;  277 1549-1551
    CrossrefPubMedGoogle Scholar
  • 7 Stephenson M D. Frequency of factors associated with habitual abortion in 197 couples.  Fertil Steril. 1996;  66 24-29
    PubMedGoogle Scholar
  • 8 Rai R S, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies.  Hum Reprod. 1995;  10 3301-3304
    PubMedGoogle Scholar
  • 9 Branch D W, Silver R, Pierangeli S, van Leeuwen I, Harris E N. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome.  Obstet Gynecol. 1997;  89 549-555
    CrossrefPubMedGoogle Scholar
  • 10 Hughes G R. The antiphospholipid syndrome: ten years on.  Lancet. 1993;  342 341-344
    CrossrefPubMedGoogle Scholar
  • 11 Hughes G R. Hughes syndrome-the syndrome behind the name (otherwise known as antiphospholipid syndrome).  Isr Med Assoc J. 1999;  1 100-103
    PubMedGoogle Scholar
  • 12 Kutteh W H. Antiphospholipid antibodies and reproduction.  J Reprod Immunol. 1997;  35 151-171
    PubMedGoogle Scholar
  • 13 Geva E, Amit A, Lerner-Geva L, Lessing J B. Autoimmunity and reproduction.  Fertil Steril. 1997;  67 599-611
    CrossrefPubMedGoogle Scholar
  • 14 Hatasaka H H, Branch D W, Kutteh W H, Scott J R. Autoantibody screening for infertility: explaining the unexplained?.  J Reprod Immunol. 1997;  34 137-153
    PubMedGoogle Scholar
  • 15 Van Voorhis B J, Stovall D W. Autoantibodies and infertility: a review of the literature.  J Reprod Immunol. 1997;  33 239-256
    PubMedGoogle Scholar
  • 16 Hornstein M D, Davis O K, Massey J B, Paulson R J, Collins J A. Antiphospholipid antibodies and in vitro fertilization success: a meta-analysis.  Fertil Steril. 2000;  73 330-333
    CrossrefPubMedGoogle Scholar
  • 17 Wasserman A, Neisser A, Bruck C. Eine serodiagnostiche Reaktion bei Syphilis.  Dtsch Med Wochenschr. 1906;  32 745-746
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 18 Pangborn M C. A new serologically active phospholipid from beef heart.  Proc Soc Exp Biol Med. 1941;  48 484-486
    CrossrefPubMedGoogle Scholar
  • 19 Moore J E, Mohr C F. Biologically false positive serologic tests for syphilis.  JAMA. 1952;  150 467-473
    PubMedGoogle Scholar
  • 20 Conley C L, Hartman R C. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus.  J Clin Invest. 1952;  31 621
    PubMedGoogle Scholar
  • 21 Bell W N, Alton H. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test.  Nature. 1954;  174 880-881
    PubMedGoogle Scholar
  • 22 Bowie E, Thompson Jr J, Pascuzzi C A, Owen Jr C. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants.  J Lab Clin Med. 1963;  62 416-430
    PubMedGoogle Scholar
  • 23 Laurell A, Nilsson I M. Hypergammaglobulinemia, circulating anticoagulant, and biologic false positive Wassermann reaction; a study in two cases.  J Lab Clin Med. 1957;  49 694-707
    PubMedGoogle Scholar
  • 24 Beaumont J L. Acquired hemorrhagic syndrome caused by a circulating anticoagulant; inhibition of the thromboplastic function of the blood platelets; description of a specific test.  Sang. 1954;  25 1-15
    PubMedGoogle Scholar
  • 25 Nilsson I M, Astedt B, Hedner U, Berezin D. Intrauterine death and circulating anticoagulant (“antithromboplastin”).  Acta Med Scand. 1975;  197 153-159
    PubMedGoogle Scholar
  • 26 Carreras L O, Defreyn G, Machin S J et al.. Arterial thrombosis, intrauterine death and “lupus” anticoagulant: detection of immunoglobulin interfering with prostacyclin formation.  Lancet. 1981;  1 241-246
    PubMedGoogle Scholar
  • 27 Hughes G R. The anticardiolipin syndrome.  Clin Exp Rheumatol. 1985;  3 285-286
    PubMedGoogle Scholar
  • 28 Harris E N, Gharavi A E, Boey M L et al.. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.  Lancet. 1983;  2 1211-1214
    PubMedGoogle Scholar
  • 29 Hughes G R. Hughes' syndrome: the antiphospholipid syndrome. A historical view.  Lupus. 1998;  7(suppl 2) S1-S4
    CrossrefPubMedGoogle Scholar
  • 30 Harris E N. Syndrome of the black swan.  Br J Rheumatol. 1987;  26 324-326
    CrossrefPubMedGoogle Scholar
  • 31 Galli M, Comfurius P, Maassen C et al.. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.  Lancet. 1990;  335 1544-1547
    CrossrefPubMedGoogle Scholar
  • 32 McNeil H P, Simpson R J, Chesterman C N, Krilis S A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).  Proc Natl Acad Sci USA. 1990;  87 4120-4124
    CrossrefPubMedGoogle Scholar
  • 33 Roubey R AS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other “antiphospholipid” antibodies.  Blood. 1994;  84 2854-2867
    PubMedGoogle Scholar
  • 34 Hunt J E, McNeil H P, Morgan G J, Crameri R M, Krilis S A. A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection.  Lupus. 1992;  1 75-81
    CrossrefPubMedGoogle Scholar
  • 35 Lubbe W F, Butler W S, Palmer S J, Liggins G C. Fetal survival after prednisone suppression of maternal lupus-anticoagulant.  Lancet. 1983;  1 1361-1363
    PubMedGoogle Scholar
  • 36 6th International Symposium on Antiphospholipid Antibodies. Leuven, Belgium, 14-17 September 1994. Proceedings.  Lupus. 1994;  3 207-364
    CrossrefPubMedGoogle Scholar
  • 37 Oshiro B T, Silver R M, Scott J R, Yu H, Branch D W. Antiphospholipid antibodies and fetal death.  Obstet Gynecol. 1996;  87 489-493
    CrossrefPubMedGoogle Scholar
  • 38 Lockshin M D, Druzin M, Goei S et al.. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus.  N Engl J Med. 1985;  313 152-156
    PubMedGoogle Scholar
  • 39 De Wolf F, Carreras L O, Moerman P, Vermylen J, Van A A, Renaer M. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant.  Am J Obstet Gynecol. 1982;  142 829-834
    CrossrefPubMedGoogle Scholar
  • 40 Levine J S, Branch D W, Rauch J. The antiphospholipid syndrome.  N Engl J Med. 2002;  346 752-763
    CrossrefPubMedGoogle Scholar
  • 41 Brandt J T, Triplett D A, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH.  Thromb Haemost. 1995;  74 1185-1190
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 42 Favaloro E J, Silvestrini R, Mohammed A. Clinical utility of anticardiolipin antibody assays: High inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach.  Pathology. 1999;  31 142-147
    CrossrefPubMedGoogle Scholar
  • 43 Silver R M, Porter T F, van Leeuween I, Jeng G, Scott J R, Branch D W. Anticardiolipin antibodies: clinical consequences of “low titers”.  Obstet Gynecol. 1996;  87 494-500
    CrossrefPubMedGoogle Scholar
  • 44 Yetman D L, Kutteh W H. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies.  Fertil Steril. 1996;  66 540-546
    PubMedGoogle Scholar
  • 45 Aoki K, Hayashi Y, Hirao Y, Yagami Y. Specific antiphospholipid antibodies as a predictive variable in patients with recurrent pregnancy loss.  Am J Reprod Immunol. 1993;  29 82-87
    PubMedGoogle Scholar
  • 46 Carreras L O, Forastiero R R, Marttunen M E. Which are the best biological markers of the antiphospholipid syndrome?.  J Autoimmun. 2000;  15 163-172
    CrossrefPubMedGoogle Scholar
  • 47 Cabral A R, Amigo M C, Cabiedes J, Alarcon-Segovia D. The antiphospholipid/cofactor syndromes: a primary variant with antibodies to b2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays.  Am J Med. 1996;  101 472-481
    CrossrefPubMedGoogle Scholar
  • 48 Lee R M, Emlen W, Scott J R, Branch D W, Silver R M. Anti-beta2-glycoprotein I antibodies in women with recurrent spontaneous abortion, unexplained fetal death, and antiphospholipid syndrome.  Am J Obstet Gynecol. 1999;  181 642-648
    PubMedGoogle Scholar
  • 49 Bertolaccini M L, Roch B, Amengual O, Atsumi T, Khamashta M A, Hughes G R. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome.  Br J Rheumatol. 1998;  37 1229-1232
    CrossrefPubMedGoogle Scholar
  • 50 Adler R R, Ng A K, Rote N S. Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR.  Biol Reprod. 1995;  53 905-910
    CrossrefPubMedGoogle Scholar
  • 51 Katsuragawa H, Kanzaki H, Inoue T, Hirano T, Mori T, Rote N S. Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion.  Biol Reprod. 1997;  56 50-58
    CrossrefPubMedGoogle Scholar
  • 52 Sebire N J, Backos M, El Gaddal S, Goldin R D, Regan L. Placental pathology, antiphospholipid antibodies, and pregnancy outcome in recurrent miscarriage patients.  Obstet Gynecol. 2003;  101 258-263
    CrossrefPubMedGoogle Scholar
  • 53 Sebire N J, Fox H, Backos M, Rai R, Paterson C, Regan L. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure.  Hum Reprod. 2002;  17 1067-1071
    CrossrefPubMedGoogle Scholar
  • 54 Burrows T D, King A, Loke Y W. Trophoblast migration during human placental implantation.  Hum Reprod Update. 1996;  2 307-321
    CrossrefPubMedGoogle Scholar
  • 55 Quenby S, Mountfield S, Cartwright J E, Whitley G S, Chamley L, Vince G. Antiphospholipid antibodies prevent extravillous trophoblast differentiation.  Fertil Steril. 2005;  83 691-698
    CrossrefPubMedGoogle Scholar
  • 56 Di Simone N, Caliandro D, Castellani R, Ferrazzani S, De Carolis S, Caruso A. Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome.  Hum Reprod. 1999;  14 489-495
    PubMedGoogle Scholar
  • 57 Cariou R, Tobelem G, Soria C, Caen J. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant.  N Engl J Med. 1986;  314 1193-1194
    CrossrefPubMedGoogle Scholar
  • 58 Cosgriff T M, Martin B A. Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis.  Arthritis Rheum. 1981;  24 94-96
    CrossrefPubMedGoogle Scholar
  • 59 Peaceman A M, Rehnberg K A. The immunoglobulin G fraction from plasma containing antiphospholipid antibodies causes increased placental thromboxane production.  Am J Obstet Gynecol. 1992;  167 1543-1547
    PubMedGoogle Scholar
  • 60 Rand J H, Wu X X, Andree H A et al.. Pregnancy loss in the antiphospholipid-antibody syndrome-a possible thrombogenic mechanism.  N Engl J Med. 1997;  337 154-160
    CrossrefPubMedGoogle Scholar
  • 61 Wiener H M, Vardinon N, Yust I. Platelet antibody binding and spontaneous aggregation in 21 lupus anticoagulant patients.  Vox Sang. 1991;  61 111-121
    PubMedGoogle Scholar
  • 62 Lin Y-L, Wang C-T. Activation of human platelets by rabbit anticardiolipin antibodies.  Blood. 1992;  80 3135-3143
    PubMedGoogle Scholar
  • 63 Meroni P L, Raschi E, Camera M et al.. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome.  J Autoimmun. 2000;  15 237-240
    CrossrefPubMedGoogle Scholar
  • 64 Vaarala O, Alfthan G, Jauhiainen M, Leirisalo Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus.  Lancet. 1993;  341 923-925
    CrossrefPubMedGoogle Scholar
  • 65 Witztum J L, Horkko S. The role of oxidized LDL in atherogenesis: immunological response and antiphospholipid antibodies.  Ann NY Acad Sci. 1997;  811 88-96
    PubMedGoogle Scholar
  • 66 Horkko S, Miller E, Dudl E et al.. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein.  J Clin Invest. 1996;  98 815-825
    PubMedGoogle Scholar
  • 67 Voges D, Berendes R, Burger A, Demange P, Baumeister W, Huber R. Three-dimensional structure of membrane-bound annexin V. A correlative electron microscopy-X-ray crystallography study.  J Mol Biol. 1994;  238 199-213
    CrossrefPubMedGoogle Scholar
  • 68 Mosser G, Ravanat C, Freyssinet J M, Brisson A. Sub-domain structure of lipid-bound annexin-V resolved by electron image analysis.  J Mol Biol. 1991;  217 241-245
    CrossrefPubMedGoogle Scholar
  • 69 Andree H A, Hermens W T, Hemker H C. Displacement of factor Va by annexin V. In: Andree HA Phospholipid Binding and Anticoagulant Action of Annexin V. Maastricht, The Netherlands; Universitaire Pers Maastricht 1992: 73-85
    Google Scholar
  • 70 Rand J H, Wu X X, Quinn A S et al.. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay.  Am J Pathol. 2003;  163 1193-1200
    CrossrefPubMedGoogle Scholar
  • 71 Rand J H. Molecular pathogenesis of the antiphospholipid syndrome.  Circ Res. 2002;  90 29-37
    CrossrefPubMedGoogle Scholar
  • 72 Krikun G, Lockwood C J, Wu X X et al.. The expression of the placental anticoagulant protein, annexin V, by villous trophoblasts: immunolocalization and in vitro regulation.  Placenta. 1994;  15 601-612
    CrossrefPubMedGoogle Scholar
  • 73 Lyden T W, Vogt E, Ng A K, Johnson P M, Rote N S. Monoclonal antiphospholipid antibody reactivity against human placental trophoblast.  J Reprod Immunol. 1992;  22 1-14
    CrossrefPubMedGoogle Scholar
  • 74 Rand J H, Wu X X, Andree H A et al.. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a “lupus procoagulant” phenomenon.  Blood. 1998;  92 1652-1660
    CrossrefPubMedGoogle Scholar
  • 75 Wang X, Campos B, Kaetzel M A, Dedman J R. Annexin V is critical in the maintenance of murine placental integrity.  Am J Obstet Gynecol. 1999;  180 1008-1016
    CrossrefPubMedGoogle Scholar
  • 76 Rand J H, Wu X X, Guller S et al.. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion.  Am J Obstet Gynecol. 1994;  171 1566-1572
    PubMedGoogle Scholar
  • 77 Rand J H, Wu X X, Guller S, Scher J, Andree H A, Lockwood C J. Antiphospholipid immunoglobulin G antibodies reduce annexin-V levels on syncytiotrophoblast apical membranes and in culture media of placental villi.  Am J Obstet Gynecol. 1997;  177 918-923
    CrossrefPubMedGoogle Scholar
  • 78 Vogt E, Ng A K, Rote N S. Antiphosphatidylserine antibody removes annexin-V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiation.  Am J Obstet Gynecol. 1997;  177 964-972
    CrossrefPubMedGoogle Scholar
  • 79 Miyakis S, Giannakopoulos B, Krilis S A. Beta 2 glycoprotein I-function in health and disease.  Thromb Res. 2004;  114 335-346
    CrossrefPubMedGoogle Scholar
  • 80 Ieko M, Ichikawa K, Triplett D A et al.. Beta2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies.  Arthritis Rheum. 1999;  42 167-174
    CrossrefPubMedGoogle Scholar
  • 81 Schousboe I, Rasmussen M S. Synchronized inhibition of the phospholipid mediated autoactivation of factor XII in plasma by beta 2-glycoprotein I and anti-beta 2-glycoprotein I.  Thromb Haemost. 1995;  73 798-804
    PubMedGoogle Scholar
  • 82 Shi T, Iverson G M, Qi J C et al.. Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I.  Proc Natl Acad Sci USA. 2004;  101 3939-3944
    CrossrefPubMedGoogle Scholar
  • 83 Bas de L H, Derksen R H, de Groot P G. beta2-glycoprotein I, the playmaker of the antiphospholipid syndrome.  Clin Immunol. 2004;  112 161-168
    CrossrefPubMedGoogle Scholar
  • 84 Amengual O, Atsumi T, Khamashta M A, Hughes G R. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome.  Thromb Haemost. 1998;  79 276-281
    PubMedGoogle Scholar
  • 85 Gharavi A E, Pierangeli S S, Colden-Stanfield M, Liu X W, Espinola R G, Harris E N. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro.  J Immunol. 1999;  163 2922-2927
    PubMedGoogle Scholar
  • 86 Rote N S, Vogt E, DeVere G, Obringer A R, Ng A K. The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome.  Am J Reprod Immunol. 1998;  39 125-136
    PubMedGoogle Scholar
  • 87 Di Simone N, Raschi E, Testoni C et al.. Pathogenic role of anti-{beta}2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of {beta}2-glycoprotein I binding to trophoblast cells and functional effects of anti-{beta}2-glycoprotein I antibodies in vitro.  Ann Rheum Dis. 2005;  64 462-467
    PubMedGoogle Scholar
  • 88 Sheng Y, Reddel S W, Herzog H et al.. Impaired thrombin generation in beta 2-glycoprotein I null mice.  J Biol Chem. 2001;  276 13817-13821
    PubMedGoogle Scholar
  • 89 Robertson S A, Roberts C T, van Beijering E et al.. Effect of beta2-glycoprotein I null mutation on reproductive outcome and antiphospholipid antibody-mediated pregnancy pathology in mice.  Mol Hum Reprod. 2004;  10 409-416
    CrossrefPubMedGoogle Scholar
  • 90 Yasuda S, Tsutsumi A, Chiba H et al.. beta(2)-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis.  Atherosclerosis. 2000;  152 337-346
    CrossrefPubMedGoogle Scholar
  • 91 Blank M, Shoenfeld Y. Beta-2-glycoprotein-I, infections, antiphospholipid syndrome and therapeutic considerations.  Clin Immunol. 2004;  112 190-199
    CrossrefPubMedGoogle Scholar
  • 92 Girardi G, Salmon J B. The role of complement in pregnancy and fetal loss.  Autoimmunity. 2003;  36 19-26
    CrossrefPubMedGoogle Scholar
  • 93 Salmon J E, Girardi G. The role of complement in the antiphospholipid syndrome.  Curr Dir Autoimmun. 2004;  7 133-148
    PubMedGoogle Scholar
  • 94 Salmon J E, Girardi G, Holers V M. Activation of complement mediates antiphospholipid antibody-induced pregnancy loss.  Lupus. 2003;  12 535-538
    CrossrefPubMedGoogle Scholar
  • 95 Di Simone N, Meroni P L, de Papa N et al.. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I.  Arthritis Rheum. 2000;  43 140-150
    CrossrefPubMedGoogle Scholar
  • 96 Pierangeli S S, Colden-Stanfield M, Liu X, Barker J H, Anderson G L, Harris E N. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo.  Circulation. 1999;  99 1997-2002
    CrossrefPubMedGoogle Scholar
  • 97 Tedesco F, Narchi G, Radillo O, Meri S, Ferrone S, Betterle C. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins.  J Immunol. 1993;  151 1562-1570
    PubMedGoogle Scholar
  • 98 Holers V M, Girardi G, Mo L et al.. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.  J Exp Med. 2002;  195 211-220
    CrossrefPubMedGoogle Scholar
  • 99 Girardi G, Berman J, Redecha P et al.. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.  J Clin Invest. 2003;  112 1644-1654
    CrossrefPubMedGoogle Scholar
  • 100 Cowchock F S, Reece E A, Balaban D, Branch D W, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment.  Am J Obstet Gynecol. 1992;  166 1318-1323
    PubMedGoogle Scholar
  • 101 Stephenson M D, Ballem P J, Tsang P et al.. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin.  J Obstet Gynaecol Can. 2004;  26 729-734
    PubMedGoogle Scholar
  • 102 Noble L S, Kutteh W H, Lashey N, Franklin R D, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin.  Fertil Steril. 2005;  83 684-690
    CrossrefPubMedGoogle Scholar
  • 103 Bose P, Black S, Kadyrov M et al.. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure.  Am J Obstet Gynecol. 2005;  192 23-30
    CrossrefPubMedGoogle Scholar
  • 104 Di Simone N, Ferrazzani S, Castellani R, De Carolis S, Mancuso S, Caruso A. Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera.  Hum Reprod. 1997;  12 2061-2065
    CrossrefPubMedGoogle Scholar
  • 105 Franklin R D, Kutteh W H. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro.  Obstet Gynecol. 2003;  101 455-462
    CrossrefPubMedGoogle Scholar
  • 106 Girardi G, Redecha P, Salmon J E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation.  Nat Med. 2004;  10 1222-1226
    CrossrefPubMedGoogle Scholar
  • 107 Spinnato J A, Clark A L, Pierangeli S S, Harris E N. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy.  Am J Obstet Gynecol. 1995;  172 690-694
    CrossrefPubMedGoogle Scholar
  • 108 Pattison N S, Chamley L W, Birdsall M, Zanderigo A M, Liddell H S, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial.  Am J Obstet Gynecol. 2000;  183 1008-1012
    CrossrefPubMedGoogle Scholar
  • 109 Cowchock S, Reece E A. Do low-risk pregnant women with antiphospholipid antibodies need to be treated?.  Am J Obstet Gynecol. 1997;  176 1099-1100
    CrossrefPubMedGoogle Scholar
  • 110 Tulppala M, Marttunen M, Soderstrom-Anttila V et al.. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production.  Hum Reprod. 1997;  12 1567-1572
    CrossrefPubMedGoogle Scholar
  • 111 Kutteh W H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.  Am J Obstet Gynecol. 1996;  174 1584-1589
    CrossrefPubMedGoogle Scholar
  • 112 Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies).  BMJ. 1997;  314 253-257
    CrossrefPubMedGoogle Scholar
  • 113 Silver R K, MacGregor S N, Sholl J S, Hobart J M, Neerhof M G, Ragin A. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients.  Am J Obstet Gynecol. 1993;  169 1411-1417
    PubMedGoogle Scholar
  • 114 Laskin C A, Bombardier C, Hannah M E et al.. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss.  N Engl J Med. 1997;  337 148-153
    CrossrefPubMedGoogle Scholar
  • 115 Gardlund B. The lupus inhibitors in thromboembolic disease and intrasuterine fetal death in the absence of systemic lupus.  Acta Med Scand. 1984;  5 293-298
    PubMedGoogle Scholar
  • 116 Kandrotas R J. Heparin pharmacokinetics and pharmacodynamics.  Clin Pharmacokinet. 1992;  22 359-374
    PubMedGoogle Scholar
  • 117 Kutteh W H, Ermel L D. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin.  Am J Reprod Immunol. 1996;  35 402-407
    CrossrefPubMedGoogle Scholar
  • 118 Farquharson R G, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment.  Obstet Gynecol. 2002;  100 408-413
    CrossrefPubMedGoogle Scholar
  • 119 Branch D W, Peaceman A M, Druzin M et al.. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group.  Am J Obstet Gynecol. 2000;  182 122-127
    CrossrefPubMedGoogle Scholar
  • 120 Ensom M HH, Stephenson M D. Low-molecular-weight heparins in pregnancy.  Pharmacotherapy. 1999;  19 1013-1025
    CrossrefPubMedGoogle Scholar
  • 121 Triolo G, Ferrante A, Ciccia F et al.. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies.  Arthritis Rheum. 2003;  48 728-731
    CrossrefPubMedGoogle Scholar
  • 122 Clark A L, Branch D W, Silver R M, Harris E N, Pierangeli S, Spinnato J A. Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy.  Obstet Gynecol. 1999;  93 437-441
    CrossrefPubMedGoogle Scholar
  • 123 Stephenson M D, Houlihan E, Tsang P, Ensworth S, Lim K, Ballem P J. Concomitant use of IVIG for treatment of the antiphospholipid antibody syndrome (APS) when ASA and heparin results in at least one adverse pregnancy outcome.  Lupus. 2002;  11 694
    PubMedGoogle Scholar
  • 124 Lynch A, Marlar R, Murphy J et al.. Antiphospholipid antibodies in predicting adverse pregnancy outcome.  Ann Intern Med. 1994;  120 470-475
    PubMedGoogle Scholar
  • 125 Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy.  Obstet Gynecol. 1995;  86 555-559
    PubMedGoogle Scholar
  • 126 Petri M. Epidemiology of the antiphospholipid antibody syndrome.  J Autoimmun. 2000;  15 145-151
    CrossrefPubMedGoogle Scholar
  • 127 Lockshin M D, Druzin M L, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody.  Am J Obstet Gynecol. 1989;  160 439-443
    PubMedGoogle Scholar
  • 128 Bahar A M, Kwak J Y, Beer A E et al.. Antibodies to phospholipids and nuclear antigens in non-pregnant women with unexplained spontaneous recurrent abortions.  J Reprod Immunol. 1993;  24 213-222
    CrossrefPubMedGoogle Scholar
  • 129 Ruiz J E, Cubillos J, Mendoza J C, Espinel F J, Kwak J Y, Beer A E. Autoantibodies to phospholipids and nuclear antigens in non-pregnant and pregnant Columbian women with recurrent spontaneous abortions.  J Reprod Immunol. 1995;  28 41-51
    PubMedGoogle Scholar
  • 130 Kutteh W H, Franklin R D. Assessing the variation in antiphospholipid antibody (APA) assays: comparison of results from 10 centers.  Am J Obstet Gynecol. 2004;  191 440-448
    CrossrefPubMedGoogle Scholar

Mary D StephensonM.D. 

Department of Obstetrics & Gynecology, Section of Reproductive Endocrinology & Infertility, University of Chicago, 5841 South Maryland Avenue (MC 2050), Chicago, IL 60637

eMail: mstephen@babies.bsd.uchicago.edu